Gizem Yilmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gizem Yilmaz has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ayten Aliyeva
Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa Cerrahpasa Medical School, Istanbul, Turkey
2 shared publications - Fatih Haslak
Department of Pediatric Rheumatology, Istanbul Medeniyet University , Istanbul
2 shared publications - Ilayda Altun
Department of Pediatrics, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
2 shared publications - Kenan Barut
Department of Pediatric Rheumatology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Türkiye
2 shared publications - Mehmet Yildiz
Department of Pediatric Rheumatology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Türkiye
2 shared publications - Memnune Nur Cebi
Department of Pediatrics, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-9
Neurodevelopmental outcomes in children with transient hypothyroxinemia of prematurity assessed using the Denver Developmental Screening Test II (DDST-II)
Objective: This study aimed to evaluate the impact of levothyroxine supplementation on neurodevelopmental outcomes in infants with transient hypothyroxinemia of prematurity (THOP). Subjects and methods: In this retrospective observational study, infants born at < 34 weeks of gestation were categorized into three groups: THOP treated with levothyroxine, untreated THOP, and non-hypothyroxinemic controls. Neurodevelopmental outcomes were assessed at 12–72 months of corrected age using the Denver Developmental Screening Test II (DDST-II). Results: Fifty-four infants (40.7% female) with a median gestational [...] ABSTRACT Objective: This study aimed to evaluate the impact of levothyroxine supplementation on neurodevelopmental outcomes in infants with transient hypothyroxinemia of prematurity (THOP). Subjects and methods: In this retrospective observational study, infants born at < 34 weeks of gestation were categorized into three groups: THOP treated with levothyroxine, untreated THOP, and non-hypothyroxinemic controls. Neurodevelopmental outcomes were assessed at 12–72 months of corrected age using the Denver Developmental Screening Test II (DDST-II). Results: Fifty-four infants (40.7% female) with a median gestational
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-9
Open AccessNeurodevelopmental outcomes in children with transient hypothyroxinemia of prematurity assessed using the Denver Developmental Screening Test II (DDST-II)
Objective: This study aimed to evaluate the impact of levothyroxine supplementation on neurodevelopmental outcomes in infants with transient hypothyroxinemia of prematurity (THOP). Subjects and methods: In this retrospective observational study, infants born at < 34 weeks of gestation were categorized into three groups: THOP treated with levothyroxine, untreated THOP, and non-hypothyroxinemic controls. Neurodevelopmental outcomes were assessed at 12–72 months of corrected age using the Denver Developmental Screening Test II (DDST-II). Results: Fifty-four infants (40.7% female) with a median gestational [...] ABSTRACT Objective: This study aimed to evaluate the impact of levothyroxine supplementation on neurodevelopmental outcomes in infants with transient hypothyroxinemia of prematurity (THOP). Subjects and methods: In this retrospective observational study, infants born at < 34 weeks of gestation were categorized into three groups: THOP treated with levothyroxine, untreated THOP, and non-hypothyroxinemic controls. Neurodevelopmental outcomes were assessed at 12–72 months of corrected age using the Denver Developmental Screening Test II (DDST-II). Results: Fifty-four infants (40.7% female) with a median gestational
- 9 September 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (8) , 2645-2651
Urinary neopterin and biopterin indicate that inflammation has a role in autism spectrum disorder
Inflammation is thought to be involved in the pathogenesis of autism spectrum disorder (ASD). Pteridine metabolites are biomarkers of inflammation that increase on immune system activation. In this study, we investigated the urinary pteridine metabolites in ASD patients as a possible biomarker for immune activation and inflammation. This observational, cross-sectional, prospective study collected urine samples from 212 patients with ASD and 68 age- and sex-matched healthy individuals. Urine neopterin (NE) and biopterin (BIO) levels were measured. Patients who had chronic disorders, active infection at the time of sampling, or high C-reactive protein levels were excluded. The urine NE and BIO concentrations were determined by high-performance liquid chromatography. The ratios of both NE and BIO to creatinine (CRE) were used to standardise the measurements. The NE/CRE and NE/BIO levels were significantly higher in ASD patients than controls. Univariate and multivariate models revealed a significant increase in NE/CRE and NE/BIO in ASD patients. There was a significant relationship between the NE/BIO [average area under the curve (AUC) = 0.717; range: 0.637–0.797] and NE/CRE (average AUC = 0.756; range: 0.684–0.828) ratios, which distinguished individuals with ASD from controls. The elevated NE/CRE and NE/BIO ratios suggest that inflammation and T cell-mediated immunity are involved in the pathophysiology of autism. NE/BIO could serve as a diagnostic inflammatory marker in the pathogenesis of ASD.
- 9 September 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (8) , 2645-2651
Urinary neopterin and biopterin indicate that inflammation has a role in autism spectrum disorder
Inflammation is thought to be involved in the pathogenesis of autism spectrum disorder (ASD). Pteridine metabolites are biomarkers of inflammation that increase on immune system activation. In this study, we investigated the urinary pteridine metabolites in ASD patients as a possible biomarker for immune activation and inflammation. This observational, cross-sectional, prospective study collected urine samples from 212 patients with ASD and 68 age- and sex-matched healthy individuals. Urine neopterin (NE) and biopterin (BIO) levels were measured. Patients who had chronic disorders, active infection at the time of sampling, or high C-reactive protein levels were excluded. The urine NE and BIO concentrations were determined by high-performance liquid chromatography. The ratios of both NE and BIO to creatinine (CRE) were used to standardise the measurements. The NE/CRE and NE/BIO levels were significantly higher in ASD patients than controls. Univariate and multivariate models revealed a significant increase in NE/CRE and NE/BIO in ASD patients. There was a significant relationship between the NE/BIO [average area under the curve (AUC) = 0.717; range: 0.637–0.797] and NE/CRE (average AUC = 0.756; range: 0.684–0.828) ratios, which distinguished individuals with ASD from controls. The elevated NE/CRE and NE/BIO ratios suggest that inflammation and T cell-mediated immunity are involved in the pathophysiology of autism. NE/BIO could serve as a diagnostic inflammatory marker in the pathogenesis of ASD.
- Open Access
- 25 April 2022
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 64 (2) , 385-388
Primitive neuroectodermal tumor in a child with Currarino syndrome
Background. Curarino syndrome is a rare and complex anomaly with the triad of anorectal malformation, presacral mass and sacral bone deformation. The most common cause of the presacral mass is meningioma, but teratoma is the diagnosis in about one-third of the cases. Malignant transformation of teratoma in the form of carcinoma, rhabdomyosarcoma and leukemia have previously been reported on rare occasions. Case. A 19 month-old-girl was referred with a presacral mass of 29mm x 23mm x 24mm. She was diagnosed as Currarino syndrome. The presacral mass was surgically resected and pathological examination revealed a foci of primitive neurectodermal tumor. Conclusions. This is the first case of Currarino syndrome with a primitive neuroectodermal tumor (PNET) foci in the presacral mass. Considering the risk of malignant transformation, the accurate pathological examination is important for complete systemic evaluation and treatment plan in these children.
- 25 April 2022
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 64 (2) , 385-388
Open AccessPrimitive neuroectodermal tumor in a child with Currarino syndrome
Background. Curarino syndrome is a rare and complex anomaly with the triad of anorectal malformation, presacral mass and sacral bone deformation. The most common cause of the presacral mass is meningioma, but teratoma is the diagnosis in about one-third of the cases. Malignant transformation of teratoma in the form of carcinoma, rhabdomyosarcoma and leukemia have previously been reported on rare occasions. Case. A 19 month-old-girl was referred with a presacral mass of 29mm x 23mm x 24mm. She was diagnosed as Currarino syndrome. The presacral mass was surgically resected and pathological examination revealed a foci of primitive neurectodermal tumor. Conclusions. This is the first case of Currarino syndrome with a primitive neuroectodermal tumor (PNET) foci in the presacral mass. Considering the risk of malignant transformation, the accurate pathological examination is important for complete systemic evaluation and treatment plan in these children.
- Open Access
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A181.1-A181
433 Long term follow-up of the patients with anti nuclear antibody positivity who had initially no identifiable rheumatic diseases
Anti-nuclear antibodies (ANA) are a group of the antibodies that develop against intracellular components of the cells. It is usually useful for diagnosing some of the connective tissue diseases like systemic lupus erythematosus, mixed connective tissue disease. But it is reported that its positivity rate is about in healthy individuals. Therefore, it can be confusing to check ANA test, if there is not really high suspicion for connective tissue diseases or juvenile idiopathic arthritis. We aimed to evaluate results of long-term follow-up of the patients with ANA positivity who had initially no identifiable rheumatic diseases. Six hundred and ninety-four patients with ANA positivity who did not diagnosed as any of the rheumatic diseases at the first examination were found in database. Two hundred and eightytwo patients of them were called so far and questioned about their demographic features and symptoms that are related with rheumatic diseases. Mean age of the patients at the time of study and at the time of testing were 13.4± 4.5 and 9.1±4.0 years. The female: male ratio was 1.05. Mean follow-up duration was 4.3±2.8 years. Most common reasons for the request for ANA test were arthralgia (n:99 (D.1)) and skin eruptions (n: 54 (24.1)). ANA testing was most commonly requested by a general pediatrists. Most of the diseases(Hypermobility Syndrome, Urticaria, Hypothyroidism, Transient synovitis, Idiopathic Thrombocytopenic Purpura, Scoliosis) were diagnosed in patients with ANA positivity were not related with autoimmune mechanisms that associated with ANA positivity therefore, these diseases are thought to be coincidence. Only in 1 patients, systemic lupus erythematosus that has certain association with ANA positivity were diagnosed. We are reporting that in only 0.3% of patients with ANA positivity who don’t have any diseases diagnosed initially, were diagnosed as rheumatologic diseases during to the follow-up period. Since positivity of ANA is also common in the healthy population, requesting this test in only patients with high suspicion for connective tissue disease will reduce confusion in terms of diagnosis.
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A181.1-A181
Open Access433 Long term follow-up of the patients with anti nuclear antibody positivity who had initially no identifiable rheumatic diseases
Anti-nuclear antibodies (ANA) are a group of the antibodies that develop against intracellular components of the cells. It is usually useful for diagnosing some of the connective tissue diseases like systemic lupus erythematosus, mixed connective tissue disease. But it is reported that its positivity rate is about in healthy individuals. Therefore, it can be confusing to check ANA test, if there is not really high suspicion for connective tissue diseases or juvenile idiopathic arthritis. We aimed to evaluate results of long-term follow-up of the patients with ANA positivity who had initially no identifiable rheumatic diseases. Six hundred and ninety-four patients with ANA positivity who did not diagnosed as any of the rheumatic diseases at the first examination were found in database. Two hundred and eightytwo patients of them were called so far and questioned about their demographic features and symptoms that are related with rheumatic diseases. Mean age of the patients at the time of study and at the time of testing were 13.4± 4.5 and 9.1±4.0 years. The female: male ratio was 1.05. Mean follow-up duration was 4.3±2.8 years. Most common reasons for the request for ANA test were arthralgia (n:99 (D.1)) and skin eruptions (n: 54 (24.1)). ANA testing was most commonly requested by a general pediatrists. Most of the diseases(Hypermobility Syndrome, Urticaria, Hypothyroidism, Transient synovitis, Idiopathic Thrombocytopenic Purpura, Scoliosis) were diagnosed in patients with ANA positivity were not related with autoimmune mechanisms that associated with ANA positivity therefore, these diseases are thought to be coincidence. Only in 1 patients, systemic lupus erythematosus that has certain association with ANA positivity were diagnosed. We are reporting that in only 0.3% of patients with ANA positivity who don’t have any diseases diagnosed initially, were diagnosed as rheumatologic diseases during to the follow-up period. Since positivity of ANA is also common in the healthy population, requesting this test in only patients with high suspicion for connective tissue disease will reduce confusion in terms of diagnosis.
- 7 January 2021
- Published by Wiley in Pediatrics International
- Vol. 63 (9) , 1020-1025
Anti‐nuclear antibody testing in children: How much is really necessary?
Background: Anti‐nuclear antibody (ANA) testing is most commonly ordered by general pediatricians to evaluate children with musculoskeletal system complaints. Given the limited utility of the test, we aimed to estimate the effectiveness of ordering ANA testing in childhood.Methods: Children referred to our department to be examined due to positive ANA findings between 2008 and 2020 were included in the study. Those with less than one‐year follow‐up period, those with previously known rheumatic or autoimmune disease, and those diagnosed as an autoimmune and/or rheumatic disease at the first visit were excluded. Data were obtained from their medical records, retrospectively. The parents of all of the patients were called via phone, data were verified, and missing information was collected.Results: Three hundred and fifty‐eight patients (230 females) were eligible for the study. The median age of positive ANA findings was 9.31 (1.3–17.86) years and the median follow‐up duration was 4.85 (1–11.91) years. Most of the patients had no underlying disease (n = 337, 94.1%). The most common reason for ordering ANA testing was to evaluate musculoskeletal system symptoms (n = 225, 62.8%). None of our patients referred to us due to positive ANA findings developed any autoimmune conditions or ANA associated rheumatic disease. Hypermobility syndrome is the most common final diagnosis among our ANA‐positive patients.Conclusion: We suggest that instead of using it as a screening tool, ANA testing should be performed only if there is a strong suspicion of autoimmune diseases or certain rheumatic conditions, such as systemic lupus erythematosus.
- 7 January 2021
- Published by Wiley in Pediatrics International
- Vol. 63 (9) , 1020-1025
Anti‐nuclear antibody testing in children: How much is really necessary?
Background: Anti‐nuclear antibody (ANA) testing is most commonly ordered by general pediatricians to evaluate children with musculoskeletal system complaints. Given the limited utility of the test, we aimed to estimate the effectiveness of ordering ANA testing in childhood.Methods: Children referred to our department to be examined due to positive ANA findings between 2008 and 2020 were included in the study. Those with less than one‐year follow‐up period, those with previously known rheumatic or autoimmune disease, and those diagnosed as an autoimmune and/or rheumatic disease at the first visit were excluded. Data were obtained from their medical records, retrospectively. The parents of all of the patients were called via phone, data were verified, and missing information was collected.Results: Three hundred and fifty‐eight patients (230 females) were eligible for the study. The median age of positive ANA findings was 9.31 (1.3–17.86) years and the median follow‐up duration was 4.85 (1–11.91) years. Most of the patients had no underlying disease (n = 337, 94.1%). The most common reason for ordering ANA testing was to evaluate musculoskeletal system symptoms (n = 225, 62.8%). None of our patients referred to us due to positive ANA findings developed any autoimmune conditions or ANA associated rheumatic disease. Hypermobility syndrome is the most common final diagnosis among our ANA‐positive patients.Conclusion: We suggest that instead of using it as a screening tool, ANA testing should be performed only if there is a strong suspicion of autoimmune diseases or certain rheumatic conditions, such as systemic lupus erythematosus.